Cyclerion Therapeutics, Inc.(CYCN)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Cyclerion Therapeutics, Inc. (CYCN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYCN at 19.3/100 on a 32-signal composite quality model, placing it at rank #2,795 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Cyclerion Therapeutics, Inc. reports net income of $-1.8M, free cash flow of $-1.4M. Top institutional holders of CYCN by reported 13-F value include Kalehua Capital Management, FMR, BALYASNY ASSET MANAGEMENT L.P., based on the most recent SEC filings. CYCN trades on the Nasdaq exchange and files with the SEC under CIK 1755237. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cyclerion Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
19.3/100
AI Rank
#2,795
Revenue
$0.00
Net Income
$-1.8M
Free Cash Flow
$-1.4M
CYCN key financials by period
Cyclerion Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.1M
$-3.5M
—
FY 2024
10-K/A
$2.0M
$-3.1M
-181.4%
FY 2022
10-K/A
$297.0K
$44.1M
—
FY 2021
10-K
$3.9M
$-51.6M
—
FY 2020
10-K
$2.3M
$-77.8M
—
FY 2019
10-K
$4.5M
$-123.0M
—
Institutions holding CYCN
Institutional investors reporting a position in Cyclerion Therapeutics, Inc. on SEC Form 13F.
